
Here's How You Can Build Up a $1 Million Portfolio Even if You Have $0 in Savings Right Now
It's never too late or too early to start investing in the stock market. Even if you don't know much about stocks, there are easy ways to gain exposure to a wide range of companies through a single investment. By doing so, you can keep your risk relatively low while also setting yourself up to achieve some significant gains over the long term.
If you don't have any money saved up today, you can still build up a portfolio of more than $1 million in the long run. As long as you have more than 30 investing years left and can afford to set aside $350 per month, you can set up a strategy for creating a portfolio worth more than $1 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
When investing for the long haul, focus on growth stocks
To maximize your gains over the years, you'll want to invest in growth stocks because they have the most upside in the long run. While it may seem challenging to track the best growth stocks, an easy way to accomplish this is by investing in an exchange-traded fund (ETF) that tracks them. The Invesco QQQ Trust (NASDAQ: QQQ) can be the ideal investment for this purpose.
The Invesco ETF holds a portfolio of 100 stocks -- the largest non-financial stocks on the Nasdaq exchange. It will rebalance and adjust over time to ensure that its holdings are reflective of the most valuable stocks on the exchange. Some examples of the stocks you'll get access to through this ETF today are Apple, Netflix, and Tesla.
The fund charges an expense ratio of 0.2%, which isn't terribly high, especially when you consider the impressive returns it has generated over the years; it has soundly outperformed the market.
S&P 500 vs QQQ data by YCharts
How many years will it take for your portfolio to reach $1 million?
Investing $350 per month in the ETF can be a great way to slowly build up your position. At that rate, you would be investing about $4,200 per year. And if you can keep up that habit for the long haul, it can potentially make you a millionaire.
Here's how your portfolio might increase in value over the years, at varying annual returns. The market has averaged a long-run return of 10% and in the table below, I've included that rate along with a scenario where the Invesco fund both does better and worse.
Year 9% Growth 10% Growth 11% Growth
30 $645,566 $797,764 $990,580
31 $710,535 $885,735 $1,109,667
32 $781,599 $982,917 $1,242,536
33 $859,328 $1,090,276 $1,390,779
34 $944,350 $1,208,877 $1,556,177
35 $1,037,347 $1,339,897 $1,740,715
Calculations by author.
If the fund averages a 10% return, it would take 33 years for your portfolio to be worth $1 million. This involves investing $350 per month throughout those years. If, however, the ETF's returns aren't that high and it averages a rate of 9% instead, it would take 35 years of regular monthly investing before your portfolio would reach $1 million.
A lot hinges on that annual return. If it's lower than you expect it to be, then you can adjust by changing your expectations and planning to invest for longer, or by adding more money to your portfolio. This can be done by either increasing the amount of your monthly investment or by adding a large lump sum to boost your balance. The more money in your portfolio that's growing and benefiting from the effects of compounding, the quicker you can get to your goal of reaching $1 million. But even with no money in your portfolio today, you can still set yourself up on a path to build up a big nest egg by the time you retire.
Should you invest $1,000 in Invesco QQQ Trust right now?
Before you buy stock in Invesco QQQ Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!*
Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
25 minutes ago
- CTV News
Bombardier secures US$1.7 billion aircraft order with service deal
Flags fly in front of signage at the Bombardier plant in Montreal, Tuesday, Feb. 4, 2025. THE CANADIAN PRESS/Christinne Muschi Bombardier said on Monday it had received an order for 50 of its Challenger and Global aircraft, alongside a service agreement, valued collectively at US$1.7 billion, with deliveries scheduled to commence in 2027. Bombardier said the customer, who has chosen to remain anonymous, would hold 70 new aircraft purchase options, which, if exercised, would increase the combined value of the aircraft and service agreements to over $4 billion. Earlier this year, the company said it expects new order activity to be slower through the first half of the year and to pick up after that. The Montreal-based company said in May that it expects to deliver more than 150 business jets this year, compared with 146 in 2024. Reporting by Gursimran Kaur in Bengaluru; Editing by Maju Samuel, Reuters


National Post
28 minutes ago
- National Post
More than 250 CN Tower workers locked out ahead of Canada Day, union says
TORONTO — More than 250 workers at the CN Tower, one of the most iconic tourist sites in Toronto, have been locked out just before Canada Day, their union said on Monday. Article content The decision to lock out workers including hosts, wait staff, bartenders and cooks at the start of peak tourist season 'speaks volumes,' and is a blow to Toronto's economy, Unifor said in a statement. Article content Article content Article content CN Tower, which is operated by Crown corporation Canada Lands Company, said on its website that although food services are temporarily closed during the labour disruption, the building's observation levels, EdgeWalk and shop remain open. Article content Article content Unifor Local 4271 said it has been fighting with the employer over a lack of pension improvements for more than 15 years and is seeking wage increases, solutions for scheduling concerns, benefits and health and safety protections. Article content The union said there has been 'no meaningful progress' on benefits throughout negotiations, and persistent health and safety issues remain unaddressed. Article content Canada Lands Company said it has been engaged in negotiations with Unifor since April and made its 'best offer' on June 26, but the union did not respond. Article content Unifor Local 4271 president Shan Ramanathan said the union is ready to return to the bargaining table at any time. Article content A Canada Lands Company spokesperson said CN Tower visitors can being their own food and non-alcoholic beverages to the observation decks while food services are closed.


National Post
38 minutes ago
- National Post
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content